FDA Approves Foundayo (orforglipron): The First Oral GLP-1 Weight Loss Pill Without Fasting Requirements
By
Elena Vega
Summary
The FDA approved Foundayo (orforglipron), a new once-daily oral GLP-1 weight loss pill by Eli Lilly, on April 1, 2026. Unlike other oral GLP-1 drugs such as Wegovy's oral semaglutide (which requires morning fasting), Foundayo can be taken at any time of day with or without food or any beverage, with no timing restrictions. The article explains how Foundayo works, its efficacy (average 12.4% weight loss), side effects, and how it compares to existing GLP-1 treatments.
Source
Key quotes
· 3 pulledFoundayo (orforglipron), developed by Eli Lilly and approved by the FDA on April 1, 2026, is a once-daily oral GLP-1 receptor agonist that can be taken at any time of day — with food, without food, or with any beverage — with no timing restrictions whatsoever.
The Wegovy pill (oral semaglutide), which was approved in December 2025, must be taken with a sip of water in the morning on an empty stomach.
Average weight loss: 12.4%.
You might also wanna read

Novo Nordisk launches first GLP-1 weight loss pill Wegovy in US at lower price than injections
Novo Nordisk has launched the first pill version of its blockbuster GLP-1 weight loss drug Wegovy in the US at a significantly lower price t

Daily weight loss pill available in UK pharmacies from today
New weight loss pill beats oral Ozempic in major trial
CVS Health to reinstate Zepbound coverage, add new weight-loss pill Foundayo to drug plans
CVS Health, through its pharmacy benefit manager CVS Caremark, will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound starti

Eli Lilly's experimental GLP-1 drug achieves 28% average weight loss, raising safety questions
Eli Lilly has released data showing its experimental GLP-1 weight-loss drug enables patients to lose an average of 28% of their body weight,

Wegovy weight-loss pill goes on sale on UK high street and online pharmacies


Comments
Sign in to join the conversation.
No comments yet. Be the first.